BioSante (NASDAQ: BPAX): LibiGel Provides Big Upside Potential

By Mike Havrilla BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception, and male testosterone deficiency (hypogonadism). The Company’s wholly-owned lead product is LibiGel (transdermal...

FDA Approves Centocor’s Psoriasis Treatment

After a long delay, Centocor Ortho Biotech‘s psoriasis drug Stelara has been approved by the U.S. Food and Drug Administration. Stelara is intended to treat moderate to severe plaque psoriasis, a skin condition that affects about 7.5 million Americans. Stelara was initially delayed in December, when...

OneMedPlace Now On Twitter and LinkedIn

Follow OneMedPlace on Twitter to discover the latest happenings in the life sciences industry.  Our Twitter page automatically notifies you of new Sentinel entries and video uploads. Click here to follow OneMedPlace on Twitter.  OneMedPlace is also on LinkedIn.  In addition, all company profiles at...

Audiopoint Introduces Phone-Based EHR System

In the push for healthcare reform, the move toward electronic health records (EHR) has been a consistent topic of discussion. The New York Times recently reported that the government’s allotment of $19 billion to encourage the adoption of EHR has led technology companies such as Dell and General...

Melanoma Drug Called a “Breakthrough” After Study

Scientists are calling Plexxikon‘s experimental skin cancer drug a “breakthrough” after it successfully shrank tumors in clinical trial patients. Researchers at Sloan-Kettering Memorial Cancer Center in New York found that PLX4032 caused tumors to shrink in 70 percent of patients with a...

Octane

Cytori’s Cardiac Celution: Encouraging Interim Data

By Mike Havrilla, BioMed Reports In the area of heart disease, Cytori Therapeutics (NASDAQ: CYTX) is sponsoring two European clinical trials that evaluate the use of adipose-derived stem and regenerative cells (ADRCs) to treat acute myocardial infarction (MI, heart attack) and chronic myocardial ischemia (a...

New Approval, Clinical Trial for YM Biosciences’ Cancer Drug

YM Biosciences, a cancer-focused product development company, has received approval to market nimotuzumab in Mexico. The company also announced that it has enrolled the first two patients in a clinical trial evaluating nimotuzumab in patients with brain tumors from non-small cell lung cancer (NSCLC). Mexico...